Artikelempfehlungen Abstract The neuroendocrine tumors NETs are more frequent during the last decades.
One of the major tools to evaluate this type of pathology is the neuroendocrine neuroendocrine cancer aggressive as chromogranin A, serotonin, urinary 5-hydroxy indolacetic acid, neuroendocrine cancer aggressive neuron specific enolase. They change related to the disease progression, regardless therapy. Some of the drugs that are used for NETs as somatostatin neuroendocrine cancer aggressive for example octreotide might interfere with glucose metabolism.
We analyzed in a retrospective study of 2 years the dynamic of the NET markers and the glycemia profile.
Еще четыре октопаука появились и в этой двери.
- Virus papiloma humano articulos
- Hpv symptoms years later
Material and Methods. All the patients had at least one assay per year. The dose of octreotide varied from 20 to 50 mg, monthly.
The fasting glucose insignificantly changed from baseline after 2 years. No new case neuroendocrine cancer aggressive diabetes was registered. One case of known diabetes needed insulin but interferon therapy was also added during this time period.
The chromogranin A had sustained high values for all the 9 cases, marking the disease progression.
REVISTA DE CHIMIE founded in edited by REVISTA DE CHIMIE SRL
The neuron specific enolase significantly increased, and the serum serotonin as well as the 5HIIA was much higher in 2 cases with aggressive carcinoid symptoms. The NET markers and the glucose metabolism are most useful tools in the management of NETs, yet they are not correlated.
MATERIALS AND METHODS: Imaging studies of 22 patients 12 men, mean age 60 years with histopathologically confirmed diagnosis, evaluated in the authors's institution during the last five years were retrospectively reviewed by two radiologists, with findings being consensually described focusing on changes observed at computed tomography.
Neuroendocrine tumors. Endocr Relat Cancer. DOI: Oberndorfer S. Karzinoide tumoren des dunndarms.
Frank Z Pathol. Carcinoid Tumors.
Bellizzi AM. Assigning site of origin in metastatic neuroendocrine neoplasms: a clinically significant application of diagnosis immunohistochemistry. Adv Anat Pathol.
Chromogranins A B C: widespread consitituents of secretory vesicles. Ann N Y Acad Sci.
Chromogranin A neuron specific enolase carcinoembryonic antigen and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. CO; 8.
Regul Pept. The neuroendocrine cancer aggressive prognosis neuroendocrine cancer aggressive in G2 neuroendocrine tumor. Rom J Morphol Embryol. The dedifferentiation of neuroendocrine tumor metastases: myth or reality? Octreotide for the treatment of hypoglycemia after insulin glargine overdose. J Emerg Med.
Services on Demand
Biochemical testing for neuroendocrine tumors. Neuroendocrine cancer aggressive clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am ;40 1 Well-differentiated neuroendocrine tumor and osteoporosis: incidental finding? Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotide.
Acta Oncol. Long-term clinical outcome neuroendocrine cancer aggressive somatostatin analogues for treatment of pregressive metastatic well-differentiated entero-pancreatic endocrine carcinoma. Ann Oncol. Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma.